Skip to main content
Diagnos Inc logo

Diagnos Inc — Investor Relations & Filings

Ticker · ADK ISIN · CA2524423068 LEI · 254900ZF529VWZDVUS82 TSXV Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 288 across all filing types
Latest filing 2026-04-08 Regulatory Filings
Country CA Canada
Listing TSXV ADK

About Diagnos Inc

https://www.diagnos.com/

Diagnos Inc. is a technology company specializing in software-based services for the healthcare sector, focusing on the early detection of critical health problems. The company leverages its proprietary FLAIRE Artificial Intelligence (AI) platform, which combines contextual imaging and data analysis to develop algorithms, process images, and analyze data. A primary application of this technology is AI retina analysis for screening and monitoring diseases, such as diabetes, to prevent vision loss. Diagnos aims to enable digital transformation in healthcare by providing cost-effective early detection solutions to primary care facilities and specialists across international markets, including North America and Latin America.

Recent filings

Filing Released Lang Actions
News release - French.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release updating investors on regulatory clearance processes for its flagship medical product (CARA) in various jurisdictions, including FDA registration and upcoming Health Canada submissions. It does not present financial results (earnings, annual or interim reports), nor is it an AGM or proxy solicitation, dividend notice, M&A announcement, share transaction, or other specified category. It is a general regulatory update and thus falls under the fallback category “Regulatory Filings (RNS).”
2026-04-08 French
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release providing corporate updates on regulatory activities and sales for the CARA product, with no financial results, board changes, share issues, or other specific transaction details. It does not attach or announce a formal report (so it is not RPA), nor is it an earnings release, management discussion, or capital/financing update. It is a general corporate/regulatory announcement, which falls under the fallback category for miscellaneous regulatory filings (RNS).
2026-04-08 English
News release - French.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release from Diagnos Inc. (OTCQB/TSXV) announcing two main items: (1) successful renewal of its medical device establishment registration with the US FDA, and (2) an amendment to extend the expiration date of outstanding warrants. There is no financial results data or earnings figures, nor is this an annual or interim report. The announcement covers a regulatory approval and a financing/capital structure change (warrant amendment), which falls under “Capital/Financing Update” rather than an earnings release or annual report. Thus, the appropriate classification is CAP.
2026-04-01 French
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release (not an AGM slide deck, earnings release, or annual report). It announces that DIAGNOS has completed its FDA device registration and, importantly, intends to amend the expiry date of 5,228,668 warrants—an update to the company’s capital structure and financing terms. This type of announcement falls squarely under “Capital/Financing Update.”
2026-04-01 English
News release - French.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release (COMMUNIQUÉ DE PRESSE) announcing two main items: (1) renewal of the company’s US‐FDA establishment registration and (2) proposed extension of the expiration date of 5,228,668 warrants. The warrant extension is a modification of the company’s capital structure and financing terms. This fits squarely within the “Capital/Financing Update” category rather than a regulatory report or routine disclosure, so the appropriate classification code is CAP.
2026-04-01 French
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing completion of FDA registration renewal and, importantly, an amendment to the expiry date of outstanding warrants (capital instruments) subject to exchange acceptance. This constitutes an update on the company’s financing activities and capital structure changes, fitting the definition of a Capital/Financing Update (CAP).
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.